Why it Matters
The Senate Judiciary Committee will consider 14 judicial and Justice Department-related nominees and legislation protecting religious freedom on Nov. 17 before turning its attention to prescription drug prices. The back-to-back sessions will give lawmakers an opportunity to advance President Donald Trump's nominees while examining whether greater competition and transparency could help lower drug costs.
The committee's executive business meeting will consider S. 5289, the Right to Worship Act, alongside the nominations, including Lee Philip Rudofsky of Arkansas for a seat on the Eighth U.S. Circuit Court of Appeals. The meeting will be followed by a hearing titled "Prescribing Sunshine: How Competition & Transparency Lowers Prescription Drug Costs."
The nominations include five federal district court judges, one U.S. Parole Commission member, three U.S. attorneys and four U.S. marshals, in addition to Rudofsky's circuit court nomination. Sen. Chuck Grassley (R-IA) chairs the committee, while Sen. Dick Durbin (D-IL) serves as ranking member.
Broader Context
The prescription drug hearing comes as Democratic lawmakers demand more information about the Trump administration's agreements with pharmaceutical companies, questioning whether the deals will deliver the savings the White House has promised.
On Nov. 10, The Hill reported that Democrats had requested details of the administration's drug-pricing agreements, seeking greater transparency into how the deals work and how much money patients and taxpayers could save.
The Washington Post reported on Nov. 9 that senior Democrats were seeking unredacted copies of the agreements. Neither report established a direct connection between the requests and the committee's hearing.
The Trump administration has also moved to require greater transparency from pharmacy benefit managers, the companies that negotiate prescription drug prices and manage drug benefits for health plans.
On Oct. 29, the Labor Department announced a final rule requiring pharmacy benefit managers and affiliated brokers and consultants to disclose fees and compensation to large employers' self-insured health plans. The rule was published in the Federal Register on Nov. 2.
The department estimates that the rule could reduce prescription drug costs for health plans and participants by as much as $22 billion over 10 years, an undiscounted projection rather than realized savings. The requirements are intended to give employers a clearer picture of the payments pharmacy benefit managers receive from drug manufacturers, pharmacies and other businesses, potentially strengthening their ability to negotiate lower costs.
The Judiciary Committee's hearing will examine similar questions about competition and transparency in the prescription drug market. Scheduled witnesses include Merith Basey, CEO of Patients For Affordable Drugs Now; Alex Oshmyansky, co-founder and CEO of Mark Cuban Cost Plus Drug Company; Matthew Pitlick, CEO of the Iowa Pharmacy Association; Neeraj Sood, a professor at the University of Southern California; and Karriem Watson, CEO of UI Health Mile Square Health Center.
The Bottom Line
The Judiciary Committee's Nov. 17 agenda brings together two separate priorities: advancing Trump's judicial and law enforcement nominees and examining how competition and transparency could lower prescription drug prices.
S. 5289 and the 14 nominees could move closer to Senate floor consideration if the committee votes to advance them. The prescription drug hearing, meanwhile, will let lawmakers question industry representatives and health policy experts as Democrats press the administration for more information about its drug-pricing agreements.
The hearing also follows the Labor Department's new pharmacy benefit manager disclosure rule, which the administration projects could save health plans and participants billions of dollars over the next decade.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article
